251 related articles for article (PubMed ID: 35305441)
1. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
Capdevila J; Awada A; Führer-Sakel D; Leboulleux S; Pauwels P
Cancer Treat Rev; 2022 May; 106():102380. PubMed ID: 35305441
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R; Elisei R; Hoff AO; Liu Z; Pitoia F; Pruneri G; Sadow PM; Soares F; Turk A; Williams MD; Wirth LJ; Cabanillas ME
JAMA Oncol; 2023 Aug; 9(8):1132-1141. PubMed ID: 37289450
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
4. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
5. EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.
Sherman SI
Trans Am Clin Climatol Assoc; 2019; 130():255-265. PubMed ID: 31516190
[TBL] [Abstract][Full Text] [Related]
6. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
Gruber JJ; Colevas AD
Oncologist; 2015 Feb; 20(2):113-26. PubMed ID: 25616432
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives on the management of patients with advanced
Elisei R; Grande E; Kreissl MC; Leboulleux S; Puri T; Fasnacht N; Capdevila J
Front Oncol; 2023; 13():1141314. PubMed ID: 37207147
[TBL] [Abstract][Full Text] [Related]
8. Advanced RAI-refractory thyroid cancer: an update on treatment perspectives.
Karapanou O; Simeakis G; Vlassopoulou B; Alevizaki M; Saltiki K
Endocr Relat Cancer; 2022 Apr; 29(5):R57-R66. PubMed ID: 35266878
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
10. [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].
Malouf G; Baudin E; Soria JC; Schlumberger M
Bull Cancer; 2009 Jan; 96(1):95-101. PubMed ID: 19211364
[TBL] [Abstract][Full Text] [Related]
11. The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies.
Iva J; Filip G; Martin B; Pavel Ž; Jan Č
Klin Onkol; 2018; 31(5):339-344. PubMed ID: 30541319
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
13. Redifferentiating Effect of Larotrectinib in
Groussin L; Theodon H; Bessiene L; Bricaire L; Bonnet-Serrano F; Cochand-Priollet B; Leroy K; Garinet S; Pasmant E; Zerbit J; Seban R; Goldwasser F; Clerc J; Cottereau AS; Huillard O
Thyroid; 2022 May; 32(5):594-598. PubMed ID: 35171708
[TBL] [Abstract][Full Text] [Related]
14. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
Sáez JM
Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
17. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
18. Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan.
Fukuda N; Tanizawa Y; Nakamura K; Okada Y; Segall G; Kiiskinen U; Fasnacht N; Sanderson I; Rider A; Lewis K
Future Oncol; 2023 May; 19(16):1125-1137. PubMed ID: 37278236
[TBL] [Abstract][Full Text] [Related]
19. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.
Hamidi S; Hofmann MC; Iyer PC; Cabanillas ME; Hu MI; Busaidy NL; Dadu R
Front Endocrinol (Lausanne); 2023; 14():1176731. PubMed ID: 37435488
[TBL] [Abstract][Full Text] [Related]
20. Thyroid Cancer: A Review.
Boucai L; Zafereo M; Cabanillas ME
JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]